Early studies on the activity of anti-TNF antibodies have demonstrated that treatment efficacy was accompanied by a decrease in synovial cellularity and a reduction of CD68+ cells in RA patients (43–45). The gene discussed is CD68; the disease is rheumatoid arthritis.